KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Receivables (2016 - 2026)

Pacira BioSciences has reported Receivables over the past 17 years, most recently at $125.6 million for Q1 2026.

  • For Q1 2026, Receivables rose 19.94% year-over-year to $125.6 million; the TTM value through Mar 2026 reached $125.6 million, up 19.94%, while the annual FY2025 figure was $124.1 million, 9.5% up from the prior year.
  • Receivables for Q1 2026 was $125.6 million at Pacira BioSciences, up from $124.1 million in the prior quarter.
  • Over five years, Receivables peaked at $125.6 million in Q1 2026 and troughed at $91.1 million in Q2 2022.
  • A 5-year average of $104.4 million and a median of $101.6 million in 2024 define the central range for Receivables.
  • Biggest five-year swings in Receivables: surged 87.04% in 2022 and later grew 1.2% in 2023.
  • Year by year, Receivables stood at $98.4 million in 2022, then grew by 7.28% to $105.6 million in 2023, then grew by 7.34% to $113.3 million in 2024, then increased by 9.5% to $124.1 million in 2025, then grew by 1.26% to $125.6 million in 2026.
  • Business Quant data shows Receivables for PCRX at $125.6 million in Q1 2026, $124.1 million in Q4 2025, and $115.3 million in Q3 2025.